
    
      IMC-001 is a PD-L1 targeting, fully human monoclonal antibody. The purpose of this study is
      to determine and evaluate the efficacy and safety of IMC-001. 20mg/kg every 2 weeks, IV
      infusion of IMC-001 will be tested in subjects with Relapsed or Refractory extranodal NK/T
      cell lymphoma, nasal type.
    
  